Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vipidia

- PMLiVE

IFPMA launches AMR Action Fund to tackle antimicrobial resistance

Pharma and health organisations unite to address public health threat

- PMLiVE

Novartis reveals full phase 3 results for Enerzair Breezhaler

Asthma treatment received EU approval earlier this week

- PMLiVE

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

Monthly meeting held remotely for the first time due to COVID-19 pandemic

- PMLiVE

Novartis forms coronavirus alliance with life sciences companies

Partnership will accelerate research with aid of Gates Foundation

- PMLiVE

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

Formally rejects extended use of SGLT2 inhibitor

- PMLiVE

Novartis says data backs safety of on-hold intrathecal Zolgensma

Data also demonstrated 'remarkable' efficacy in SMA type 2

Novartis day

Novartis donates malaria drug for COVID-19 clinical trials

Hydroxychloroquine will be evaluated for efficacy against novel coronavirus disease

- PMLiVE

EMA calls for pooled EU research into COVID-19 therapies

Asks for a harmonised methodology across member states

- PMLiVE

Novartis launches $20m COVID-19 response fund

Financial grants will be issued to most impacted communities

- PMLiVE

FDA clears wider use for Boehringer’s Ofev in lung disease

Drug was first approved in 2014 for pulmonary fibrosis

EU flag

EMA to consider coronavirus’ impact on EU medicines supply

Steering group will identify EU-wide actions to mitigate medicine supply risks

- PMLiVE

Takeda begins development of COVID-19 plasma therapy

Drug will harness the antibodies of recovered coronavirus patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links